Welwyn, United Kingdom

Andrew John Eatherton

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 6.5

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Welwyn, GB (2009)
  • Harlow, GB (2009)
  • Brentford, GB (2014)
  • Middlesex, GB (2016)

Company Filing History:


Years Active: 2009-2016

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: The Innovations of Andrew John Eatherton

Introduction

Andrew John Eatherton is a notable inventor based in Welwyn, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target LRRK2 kinase activity. With a total of four patents to his name, Eatherton's work is particularly relevant in the context of neurodegenerative diseases.

Latest Patents

Eatherton's latest patents include innovative compounds such as 2-(benzyloxy) benzamides, which serve as LRRK2 kinase inhibitors. These novel compounds are designed to inhibit LRRK2 kinase activity, which is crucial in the treatment of diseases like Parkinson's disease and Alzheimer's disease. The patents detail processes for the preparation of these compounds, compositions containing them, and their therapeutic applications.

Career Highlights

Throughout his career, Eatherton has worked with prominent companies in the pharmaceutical industry, including Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His expertise in medicinal chemistry has positioned him as a valuable asset in the development of new therapeutic agents.

Collaborations

Eatherton has collaborated with notable colleagues such as Karamjit Singh Jandu and Oliver James Philps. These collaborations have further enhanced his research and development efforts in the field of kinase inhibitors.

Conclusion

Andrew John Eatherton's contributions to the field of medicinal chemistry and his innovative patents highlight his commitment to advancing treatments for neurodegenerative diseases. His work continues to impact the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…